Highlights

  • Orthocell (ASX:OCC) reported record FY26 Revenue of A$13.2 million, up 44% year-on-year.
  • Remplir adoption increased across US hospitals, surgeons and procurement approvals.
  • The company is expanding its regenerative medicine products across additional international markets.
  • Converting early US adoption indicators into higher revenue remains the key focus.

Orthocell (ASX:OCC) has reported its strongest financial year to date, supported by increasing adoption of Remplir, its collagen nerve-repair wrap used in surgical procedures.

The FY26 update highlighted growth in revenue, hospital engagement and commercial infrastructure, particularly in the United States. However, the company remains in an early phase of US commercialisation, with future performance dependent on converting adoption indicators into recurring sales growth.

What Happened?

On 13 July 2026, Orthocell released its FY26 revenue and June quarter update, reporting record annual revenue of A$13.2 million.

June quarter revenue reached A$3.8 million, representing growth of 20% compared with the prior quarter and 36% year-on-year.

The company’s growth strategy is centred on Remplir, a collagen wrap designed to support nerve repair procedures.

Orthocell reported increased adoption across US hospitals, surgeons and hospital procurement processes as it continues expanding commercial activity.

Why It Matters

For medical technology companies, early adoption indicators can provide insight into whether commercial uptake is developing beyond initial product placements.

Orthocell reported 70 US hospitals purchasing Remplir, an increase of 27%.

The company also reported 76 surgeons using Remplir, up 55%, and 44 hospital value-analysis committee approvals, up 38%.

Hospital value-analysis approval is an important step in procurement processes, allowing products to move towards broader clinical use.

Orthocell has also expanded its distributor network, which now provides access to approximately half of the US population.

The Numbers

Orthocell reported FY26 revenue of A$13.2 million, representing 44% growth compared with the previous year.

US Remplir sales in the June quarter were approximately A$330,000, representing a 10% increase compared with the previous quarter, with 119 units sold.

Customer receipts during the quarter were A$2.5 million, compared with A$1.6 million previously.

Operating cash outflow was A$3.6 million, or A$2.4 million on a normalised basis after adjustments disclosed by the company.

Orthocell reported total available funds of A$44.1 million, including A$9.4 million in cash and equivalents and A$34.7 million in securities and term deposits.

The company reports financial results in Australian dollars, while some market opportunities are referenced in US dollars.

The Bigger Picture

Orthocell’s commercial strategy is based on two regenerative medicine products.

Remplir targets peripheral nerve repair, a market the company estimates at approximately US$1.6 billion in the United States.

Striate+ is a collagen membrane product used in dental bone regeneration and has regulatory approvals across multiple international markets.

The FY26 growth strategy is focused on expanding Remplir internationally, with approvals already in place in the United States, Australia, New Zealand and Singapore.

The company has identified potential expansion into Canada, Thailand, Europe and the United Kingdom.

The Bull Case

The positive case for Orthocell (ASX:OCC) is based on continued adoption of Remplir and expansion into additional markets.

The increase in hospitals, surgeons and procurement approvals provides a foundation for future sales growth.

As more hospitals complete approval processes and surgeons gain experience using Remplir, product ordering frequency could increase.

The company’s available funds also provide capacity to continue investing in commercial expansion.

Additional regulatory approvals could broaden the addressable market for its regenerative medicine products.

Risks Investors Should Understand

Orthocell (ASX:OCC)’s Business faces risks including commercial execution, adoption timelines, competition, reimbursement conditions and funding requirements.

While hospital approvals and surgeon adoption have increased, revenue contribution from US Remplir sales remains at an early stage.

Hospital procurement cycles can be lengthy, and product adoption does not guarantee rapid increases in ordering volumes.

The company also faces competition in regenerative medicine markets and potential delays in regulatory approvals across new regions.

As the company continues investing in expansion, maintaining an appropriate balance between growth spending and cash resources remains important.

What Comes Next?

The key focus for FY27 is converting Remplir adoption indicators into higher US revenue.

Investors will monitor growth in hospital accounts, surgeon usage, unit sales and distributor coverage.

The company will also progress international expansion opportunities and track progress towards improved operating cash generation.

Conclusion

Orthocell (ASX:OCC) delivered record FY26 revenue of A$13.2 million as Remplir adoption expanded across US hospitals and surgeons.

The company has established early commercial foundations, supported by increasing procurement approvals and a strengthened balance sheet.

However, the next stage depends on converting these leading indicators into consistent revenue growth. FY27 will provide greater clarity on whether Remplir adoption can translate into a larger commercial opportunity.